Ultrasmall Polyphenol-NAD+ Nanoparticle-Mediated Renal Delivery for Mitochondrial Repair and Anti-Inflammatory Treatment of AKI-to-CKD Progression

© 2024 Wiley‐VCH GmbH.

Bibliographische Detailangaben
Veröffentlicht in:Advanced materials (Deerfield Beach, Fla.). - 1998. - 36(2024), 30 vom: 31. Juli, Seite e2310731
1. Verfasser: Kong, Ying (VerfasserIn)
Weitere Verfasser: Chen, Xu, Liu, Feng, Tang, Jiageng, Zhang, Yijing, Zhang, Xiangxiang, Zhang, Luyao, Zhang, Tong, Wang, Yaqi, Su, Mengxiao, Zhang, Qixin, Chen, Hanxiang, Zhou, Di, Yi, Fan, Liu, Hong, Fu, Yi
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2024
Zugriff auf das übergeordnete Werk:Advanced materials (Deerfield Beach, Fla.)
Schlagworte:Journal Article acute kidney injury chronic kidney disease inflammation mitochondria nanoparticle nicotinamide adenine dinucleotide NAD 0U46U6E8UK Polyphenols mehr... Anti-Inflammatory Agents Gallic Acid 632XD903SP
LEADER 01000caa a22002652c 4500
001 NLM37293465X
003 DE-627
005 20250306061521.0
007 cr uuu---uuuuu
008 240528s2024 xx |||||o 00| ||eng c
024 7 |a 10.1002/adma.202310731  |2 doi 
028 5 2 |a pubmed25n1242.xml 
035 |a (DE-627)NLM37293465X 
035 |a (NLM)38805174 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Kong, Ying  |e verfasserin  |4 aut 
245 1 0 |a Ultrasmall Polyphenol-NAD+ Nanoparticle-Mediated Renal Delivery for Mitochondrial Repair and Anti-Inflammatory Treatment of AKI-to-CKD Progression 
264 1 |c 2024 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 25.07.2024 
500 |a Date Revised 25.07.2024 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a © 2024 Wiley‐VCH GmbH. 
520 |a As a central metabolic molecule, nicotinamide adenine dinucleotide (NAD+) can potentially treat acute kidney injury (AKI) and chronic kidney disease (CKD); however, its bioavailability is poor due to short half-life, instability, the deficiency of targeting, and difficulties in transmembrane transport. Here a physiologically adaptive gallic acid-NAD+ nanoparticle is designed, which has ultrasmall size and pH-responsiveness, passes through the glomerular filtration membrane to reach injured renal tubules, and efficiently delivers NAD+ into the kidneys. With an effective accumulation in the kidneys, it restores renal function, immune microenvironment homeostasis, and mitochondrial homeostasis of AKI mice via the NAD+-Sirtuin-1 axis, and exerts strong antifibrotic effects on the AKI-to-CKD transition by inhibiting TGF-β signaling. It also exhibits excellent stability, biodegradable, and biocompatible properties, ensuring its long-term safety, practicality, and clinical translational feasibility. The present study shows a potential modality of mitochondrial repair and immunomodulation through nanoagents for the efficient and safe treatment of AKI and CKD 
650 4 |a Journal Article 
650 4 |a acute kidney injury 
650 4 |a chronic kidney disease 
650 4 |a inflammation 
650 4 |a mitochondria 
650 4 |a nanoparticle 
650 4 |a nicotinamide adenine dinucleotide 
650 7 |a NAD  |2 NLM 
650 7 |a 0U46U6E8UK  |2 NLM 
650 7 |a Polyphenols  |2 NLM 
650 7 |a Anti-Inflammatory Agents  |2 NLM 
650 7 |a Gallic Acid  |2 NLM 
650 7 |a 632XD903SP  |2 NLM 
700 1 |a Chen, Xu  |e verfasserin  |4 aut 
700 1 |a Liu, Feng  |e verfasserin  |4 aut 
700 1 |a Tang, Jiageng  |e verfasserin  |4 aut 
700 1 |a Zhang, Yijing  |e verfasserin  |4 aut 
700 1 |a Zhang, Xiangxiang  |e verfasserin  |4 aut 
700 1 |a Zhang, Luyao  |e verfasserin  |4 aut 
700 1 |a Zhang, Tong  |e verfasserin  |4 aut 
700 1 |a Wang, Yaqi  |e verfasserin  |4 aut 
700 1 |a Su, Mengxiao  |e verfasserin  |4 aut 
700 1 |a Zhang, Qixin  |e verfasserin  |4 aut 
700 1 |a Chen, Hanxiang  |e verfasserin  |4 aut 
700 1 |a Zhou, Di  |e verfasserin  |4 aut 
700 1 |a Yi, Fan  |e verfasserin  |4 aut 
700 1 |a Liu, Hong  |e verfasserin  |4 aut 
700 1 |a Fu, Yi  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Advanced materials (Deerfield Beach, Fla.)  |d 1998  |g 36(2024), 30 vom: 31. Juli, Seite e2310731  |w (DE-627)NLM098206397  |x 1521-4095  |7 nnas 
773 1 8 |g volume:36  |g year:2024  |g number:30  |g day:31  |g month:07  |g pages:e2310731 
856 4 0 |u http://dx.doi.org/10.1002/adma.202310731  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 36  |j 2024  |e 30  |b 31  |c 07  |h e2310731